COMMONWEALTH of VIRGINIA
Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid
Drug Utilization Review (DUR) Board
Quarterly Meeting
2pm
Thursday, September 12, 2013
DMAS Board Room 13th Floor

Agenda

1. Call to Order and Introductions – Randy Ferrance, MD, Chair

2. Minutes
   a. Approval of Minutes from the May 16, 2013 meeting

3. New Drugs
   a. Non-Self-Administered Medications
   b. Self-Administered Medications
      1. Cystaran (cysteamine)
      2. Procysbi (cysteamine bitartrate)
      3. Invokana (canagliflozin)
      4. Liptruzet (ezetimibe and atorvastatin)
      5. Osphena (ospemifene)
      6. Sirturo (bedaquiline)
      7. Tecfidera (dimethyl fumarate)
      8. Tobi Podhaler (tobramycin inhalation powder)
      9. Vecamyl (mecamylamine hydrochloride)
     10. Simbrinza (brinzolamide/brimonidine tartrate)
     11. Diclegis (doxylamine succinate and pyridoxine hcl)
     12. Namenda XR (memantine hydrochloride)
     13. Afinitor Disperz (everolimus)
     14. Simponi (golimumab)
     15. Tafinlar (dabrafenib)
     16. Belviq (lorcaserin hydrochloride)
     17. Doryx (doxycycline hyclate)
     18. Mekinist (trametinib)
     19. Suprax (cefixime)
20. Revlimid (lenalidomide)

4. Old Business
   a. Ravicti

5. Reports
   a. ProDUR
   b. RetroDUR
   c. Ad hocs
   d. Utilization Analysis Reports based on Claims

6. Future Topics

7. Other Business
   a. Truvada Update
   b. Antipsychotics in Dementia
   c. Octreotide Numbers
   d. AAP Historical Report
   e. Bisphosphonate
      1. Xerox Data
      2. DMAS Data

8. Adjournment